Treprostinil Palmitil

Treprostinil Palmitil

Treprostinil palmitil drug is the generic of a brand name Tyvaso and is used to treat rare pulmonary disorders, comprising pulmonary arterial hypertension (PAH), and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Treprostinil acts as a synthetic analog of prostacyclin approved for the treatment of Group 1 or PAH. It is a drug that helps reduce pressure in the lungs and improve oxygenation in the blood vessels. It was first approved by the US FDA in 2002, and it's becoming more popular because of the rising number of people with pulmonary hypertension, drug and tech advances, approvals, and campaigns by big companies. People with PAH are also more likely to be affected by diseases like HIV, which can lead to pulmonary artery hypertension. According to the American Journal of Managed Care in March 2021, PAH being a rare disorder affects between 15 to 50 people in every million people in the US and Europe. Several factors, including a surge in the increasing government awareness programs regarding the available treatment options for pulmonary arterial hypertension, rising demand for oral drugs, and increased investments from the government, public, and private sectors in healthcare departments are driving the growth of the market during the forecast period. According to the Lung Foundation Australia, November is the designated month of pulmonary hypertension awareness (PH) in Australia. PH Awareness Month is a worldwide campaign to raise awareness of the condition, its associated symptoms, and the support needed.

The Treprostinil Palmitil Market is expected to grow at a steady rate of around 3.5% owing to the increased investment in research & development globally by pharmaceutical companies due to the surge in pulmonary hypertension cases which needs to be controlled. For instance, the Janssen Pharmaceutical Companies of Johnson & Johnson have published abstracts that highlight data from their pulmonary hypertension portfolio and their dedication to promoting scientific progress in pulmonary hypertension (PAH). These abstracts were presented at CHEST, the annual conference of the American College of Chest Physicians, which was held from October 17 to 20, 2021. Many new therapies are being introduced to treat this disease. Several other factors, such as the introduction of generic drugs and their cost-effectiveness, and government initiatives are also driving this market of treprostinil palmitil at a steady rate.

• Based on type, the market is bifurcated into branded and generic. The branded segment held the maximum share in the global market of treprostinil palmitil in 2022. This segment dominated the market because of its brand reputation. Branded drugs are better accepted in the market because of this factor. Hence, due to the above reasons, the branded segment held a significant share of the market in 2022.
• Based on mode of administration, the market is segmented into injection, inhalation, and oral. The inhalation segment is expected to hold a significant share of the market in the forecast period. Inhalation provides a more rapid onset of action than oral administration, as the drug is administered directly to the lung, with minimal exposure to the surrounding tissues. For instance, an article published in the June 2023 edition of Lung India Journal states that inhaling therapy is the most secure and successful approach to treating obstructive respiratory diseases, including asthma and chronic obstructive pulmonary disease. Apart from this, the rising number of lung disorders like asthma is boosting the patient load in hospitals and is also impelling the growth of this segment. Hence, amongst modes of administration, the inhalation category is expected to witness a higher CAGR during the forecast period.
• Based on end use, the market is segmented into hospitals, ambulatory surgical centers, and others. The hospitals held a significant share in the treprostinil palmitil market in 2022. Apart from this, the growing number of hospitals is also propelling segmental growth. For instance, according to the American Hospital Association, there were about 6,093 hospitals in the U.S. in October 2022, which comprises community hospitals run by non-profit organizations as well as by state and local governments. Hence, the hospital segment held a higher share of the market in the year 2022.
• For a better understanding of the market adoption of treprostinil palmitil, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. APAC is expected to grow with a high CAGR during the forecast period. Several factors such as a surge in high blood pressure cases among adults and adolescents in the region. For example, the Centers for Disease Control and Prevention (CDC) reported in July 2023 that the proportion of adults with hypertension, defined as blood pressure higher than 130 millimeters of mercury (mmHg) at systolic or 80 millimeters of mercury at diastolic levels, had reached a peak in 2021. Further, the increase in incidences of pulmonary hypertension, the development of a wide range of therapeutics with treprostinil palmitil, enhanced accessibility of pharmaceutical products, the presence of key generic pharmaceutical companies in the region, and the surge in government initiatives and special communities are also having a positive impact on the market’s growth. Hence, the APAC region is supposed to witness a higher CAGR during the forecast period.
• Some of the major players operating in the market include United Therapeutics Corporation; MannKind Corporation; Insmed Incorporated; Dr. Reddy’s Laboratories Ltd.; Par Pharmaceutical; Sandoz Group AG; Alembic Pharmaceuticals Limited; Teva Pharmaceutical Industries Ltd.; Pharmosa Biopharm Inc.; Liquidia Corporation.